乙酰水杨酰水杨酸结构式
|
常用名 | 乙酰水杨酰水杨酸 | 英文名 | acetylsalicylsalicylic acid |
---|---|---|---|---|
CAS号 | 530-75-6 | 分子量 | 300.263 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 540.1±35.0 °C at 760 mmHg | |
分子式 | C16H12O6 | 熔点 | 153-160ºC | |
MSDS | N/A | 闪点 | 203.9±19.4 °C |
中文名 | 乙酰水杨酰水杨酸 |
---|---|
英文名 | acetylsalicylsalicylic acid |
中文别名 | 乙酰基水杨酸 | 乙酰水杨酸杂质D |
英文别名 | 更多 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 540.1±35.0 °C at 760 mmHg |
熔点 | 153-160ºC |
分子式 | C16H12O6 |
分子量 | 300.263 |
闪点 | 203.9±19.4 °C |
精确质量 | 300.063385 |
PSA | 89.90000 |
LogP | 2.37 |
外观性状 | 白色至近乎于白色细结晶粉末 |
蒸汽压 | 0.0±1.5 mmHg at 25°C |
折射率 | 1.599 |
储存条件 | 密封储存,储存于阴凉、干燥的库房。 |
稳定性 | 常温常压下稳定,避免与不相容材料接触。 与强氧化剂反应。 |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:1 3.氢键受体数量:6 4.可旋转化学键数量:6 5.互变异构体数量:无 6.拓扑分子极性表面积89.9 7.重原子数量:22 8.表面电荷:0 9.复杂度:432 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1. 性状:白色结晶状粉末 2. 密度(g/mL,25℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):153-160 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,60mmHg):未确定 7. 折射率(n20/D):未确定 8. 闪点(ºC):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kPa,25 ºC):未确定 12. 饱和蒸气压(kPa,25ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:与水溶解 |
海关编码 | 2918990090 |
---|---|
中文概述 | 2918990090. 其他含其他附加含氧基羧酸(包括酸酐、酰卤化物、过氧化物和过氧酸及该税号的衍生物). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
[A new possible strategy for prevention and preventive treatment of age-related macular degeneration resting on recent clinical and pathophysiological observations].
Orv. Hetil. 150(11) , 503-12, (2009) The beneficial effect achieved by the treatment of endothelial dysfunction in chronic cardiovascular diseases is already an evidence belonging to the basic treatment of the disease. Given the fact tha... |
|
Solid-state stability of aspirin in the presence of excipients: kinetic interpretation, modeling, and prediction.
J. Pharm. Sci. 71(10) , 1096-101, (1982) Salicylsalicylic acid and acetylsalicylsalicylic acid were identified as decomposition products of aspirin when mixtures of the drug, with magnesium stearate, were stored in the solid state of 60 degr... |
|
Aspirin--a national survey III: Determination of impurities in bulk aspirin and aspirin formulations by high-pressure liquid chromatography and spectrophotometry.
J. Pharm. Sci. 69(5) , 550-3, (1980) A quantitative high-pressure liquid chromatographic method, using a reversed-phase column and an aqueous acetic acid-methanol solution as the mobile phase, was employed for the determination of O-acet... |
Benzoic acid, 2-(acetyloxy)-, 2-carboxyphenyl ester |
EINECS 208-493-6 |
Diplosal Acetate |
2-(Acetyloxy)benzoic Acid 2-Carboxyphenyl Ester |
2-Carboxyphenyl o-acetylsalicylate |
2-Hydroxybenzoic Acid Acetate 2-Carboxyphenyl Ester |
2-(2-acetyloxybenzoyl)oxybenzoic acid |
2-[[2-(Acetyloxy)benzoyl]oxy]benzoic acid |
2-((2-Acetoxybenzoyl)oxy)benzoic acid |
Salicylacetylsalicylic Acid |
2-[(2-Acetoxybenzoyl)oxy]benzoic acid |
2-{[2-(acetyloxy)benzoyl]oxy}benzoic acid |
Acetylsalicylsalicylic acid |
MFCD000143537 |